Free Trial
→ Trump’s Exec Order #14154 could be a “Millionaire-Maker” (From Paradigm Press) (Ad) Free ORIC Stock Alerts

Oric Pharmaceuticals (ORIC) Financials

Oric Pharmaceuticals logo
$10.65 -0.15 (-1.39%)
As of 07/7/2025 04:00 PM Eastern
Compare
Annual Income Statements for Oric Pharmaceuticals

Annual Income Statements for Oric Pharmaceuticals

This table shows Oric Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -21 -25 -74 -79 -89 -101 -128
Consolidated Net Income / (Loss)		 -21 -27 -74 -79 -89 -101 -128
Net Income / (Loss) Continuing Operations		 -21 -25 -73 -79 -89 -101 -128
Total Pre-Tax Income 		-21 -27 -74 -79 -89 -101 -128
Total Operating Income		 -22 -29 -74 -79 -92 -111 -143
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 22 29 74 79 92 111 143
Selling, General & Admin Expense		 3.35 5.73 13 22 25 26 29
Research & Development Expense		 19 23 61 57 67 85 114
Total Other Income / (Expense), net		 1.01 1.69 0.48 0.16 2.65 10 15
Basic Earnings per Share		 ($12.32) ($14.15) ($3.36) ($2.07) ($2.25) ($1.96) ($1.83)
Weighted Average Basic Shares Outstanding		 1.73M 1.90M 21.94M 37.95M 39.66M 51.45M 69.73M
Diluted Earnings per Share		 ($12.32) ($14.15) ($3.36) ($2.07) ($2.25) ($1.96) ($1.83)
Weighted Average Diluted Shares Outstanding		 1.73M 1.90M 21.94M 37.95M 39.66M 51.45M 69.73M
Weighted Average Basic & Diluted Shares Outstanding		 1.73M 1.90M 21.94M 37.95M 45.09M 67.38M 71.03M

Quarterly Income Statements for Oric Pharmaceuticals

This table shows Oric Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -25 -21 -24 -23 -25 -28 -25 -32 -34 -37 -30
Consolidated Net Income / (Loss)		 -25 -21 -24 -23 -25 -28 -25 -32 -35 -36 -30
Net Income / (Loss) Continuing Operations		 -25 -21 -24 -23 -25 -28 -25 -32 -35 -36 -30
Total Pre-Tax Income 		-25 -21 -24 -23 -25 -28 -25 -32 -35 -36 -30
Total Operating Income		 -26 -22 -26 -25 -29 -31 -29 -36 -38 -40 -33
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 26 22 26 25 29 31 29 36 38 40 33
Selling, General & Admin Expense		 5.97 5.82 6.16 6.21 6.29 6.95 7.03 7.08 7.12 7.60 8.08
Research & Development Expense		 20 16 20 19 22 24 22 29 31 32 25
Total Other Income / (Expense), net		 0.87 1.27 1.73 2.05 3.20 3.10 3.98 4.05 3.75 3.26 2.70
Basic Earnings per Share		 ($0.63) ($0.52) ($0.53) ($0.50) ($0.44) ($0.49) ($0.37) ($0.45) ($0.49) ($0.52) ($0.42)
Weighted Average Basic Shares Outstanding		 39.58M 39.66M 45.09M 45.65M 57.40M 51.45M 67.35M 70.35M 70.54M 69.73M 71.04M
Diluted Earnings per Share		 ($0.63) ($0.52) ($0.53) ($0.50) ($0.44) ($0.49) ($0.37) ($0.45) ($0.49) ($0.52) ($0.42)
Weighted Average Diluted Shares Outstanding		 39.58M 39.66M 45.09M 45.65M 57.40M 51.45M 67.35M 70.35M 70.54M 69.73M 71.04M
Weighted Average Basic & Diluted Shares Outstanding		 39.58M 45.09M 45.09M 54.53M 54.55M 67.38M 67.42M 70.54M 70.57M 71.03M 71.09M

Annual Cash Flow Statements for Oric Pharmaceuticals

This table details how cash moves in and out of Oric Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 17 47 -11 148 -159 -43 36
Net Cash From Operating Activities		 -21 -24 -45 -60 -75 -86 -113
Net Cash From Continuing Operating Activities		 -21 -24 -45 -60 -75 -86 -113
Net Income / (Loss) Continuing Operations		 -21 -27 -74 -79 -89 -101 -128
Consolidated Net Income / (Loss)		 -21 -27 -74 -79 -89 -101 -128
Depreciation Expense		 0.90 1.03 0.97 0.90 0.97 1.03 1.11
Amortization Expense		 0.00 0.00 0.30 1.35 -1.04 -6.17 -8.10
Non-Cash Adjustments To Reconcile Net Income		 0.48 1.10 25 13 15 15 20
Changes in Operating Assets and Liabilities, net		 -0.71 1.22 2.05 4.07 -0.45 4.90 1.97
Net Cash From Investing Activities		 -0.51 -0.77 -216 158 -109 -43 22
Net Cash From Continuing Investing Activities		 -0.51 -0.77 -216 158 -109 -43 22
Purchase of Property, Plant & Equipment		 -0.53 -0.77 -0.67 -0.94 -2.08 -0.85 -1.19
Purchase of Investments		 0.00 0.00 -225 -70 -238 -239 -252
Sale and/or Maturity of Investments		 0.00 0.00 10 229 131 197 275
Net Cash From Financing Activities		 38 71 251 49 25 86 127
Net Cash From Continuing Financing Activities		 38 71 251 49 25 86 127
Repayment of Debt		 - -0.10 -21 -1.85 -0.40 -0.23 -0.17
Issuance of Common Equity		 0.00 0.00 271 50 26 86 126
Other Financing Activities, net		 0.08 0.13 0.44 0.99 0.08 0.06 0.63

Quarterly Cash Flow Statements for Oric Pharmaceuticals

This table details how cash moves in and out of Oric Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 -20 38 -7.85 45 -77 -2.85 33 -6.53 -5.60 15 -10
Net Cash From Operating Activities		 -19 -15 -21 -21 -20 -24 -30 -26 -29 -28 -33
Net Cash From Continuing Operating Activities		 -19 -15 -21 -21 -20 -24 -30 -26 -29 -28 -33
Net Income / (Loss) Continuing Operations		 -25 -21 -24 -23 -25 -28 -25 -32 -35 -36 -30
Consolidated Net Income / (Loss)		 -25 -21 -24 -23 -25 -28 -25 -32 -35 -36 -30
Depreciation Expense		 0.22 0.25 0.25 0.26 0.26 0.26 0.26 0.27 0.27 0.30 0.30
Amortization Expense		 -0.37 -0.62 -0.86 -1.26 -1.92 -2.12 -2.23 -2.30 -1.95 -1.63 -0.88
Non-Cash Adjustments To Reconcile Net Income		 3.29 3.17 3.61 3.83 3.86 3.94 4.96 5.00 5.06 5.20 6.55
Changes in Operating Assets and Liabilities, net		 2.37 2.72 0.31 -1.03 3.63 1.98 -8.17 3.37 2.39 4.38 -8.49
Net Cash From Investing Activities		 -0.69 28 13 -19 -58 21 -62 18 23 43 22
Net Cash From Continuing Investing Activities		 -0.69 28 13 -19 -58 21 -62 18 23 43 22
Purchase of Property, Plant & Equipment		 -0.40 -0.29 -0.31 -0.41 -0.08 -0.06 -0.22 -0.33 -0.42 -0.22 -0.39
Purchase of Investments		 -61 -32 -43 -56 -111 -29 -114 -49 -54 -35 -65
Sale and/or Maturity of Investments		 61 60 56 37 53 50 53 68 78 78 88
Net Cash From Financing Activities		 0.00 25 0.00 85 0.03 0.45 125 0.82 0.13 0.58 0.01
Net Cash From Continuing Financing Activities		 0.00 25 0.00 85 0.03 0.45 125 0.82 0.13 0.58 0.01
Repurchase of Common Equity		 - - - - - - -0.17 - - - 0.00
Issuance of Common Equity		 - 25 0.00 85 - 0.43 125 0.52 - 0.56 0.00
Other Financing Activities, net		 0.00 0.00 0.00 - 0.03 0.03 0.20 0.29 0.13 0.01 0.01

Annual Balance Sheets for Oric Pharmaceuticals

This table presents Oric Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 94 299 299 247 252 274
Total Current Assets		 90 297 241 210 213 262
Cash & Equivalents		 89 78 226 67 23 59
Short-Term Investments		 0.00 215 11 139 185 197
Prepaid Expenses		 0.84 3.10 3.54 4.19 4.41 6.29
Plant, Property, & Equipment, net		 2.24 1.98 2.41 3.25 2.86 2.92
Total Noncurrent Assets		 1.85 0.32 56 33 37 8.97
Long-Term Investments		 - 0.00 43 22 27 0.00
Other Noncurrent Operating Assets		 1.85 0.32 12 12 9.70 8.97
Total Liabilities & Shareholders' Equity		 94 299 299 247 252 274
Total Liabilities		 6.12 9.22 26 25 28 31
Total Current Liabilities		 5.35 9.00 15 15 20 25
Accounts Payable		 0.15 0.76 1.89 1.32 0.94 1.55
Accrued Expenses		 5.20 8.25 13 14 20 23
Total Noncurrent Liabilities		 0.77 0.22 11 9.44 7.46 6.17
Other Noncurrent Operating Liabilities		 - 0.22 11 9.44 7.46 6.17
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -90 290 273 222 224 243
Total Preferred & Common Equity		 -90 290 273 222 224 243
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -90 290 273 222 224 243
Common Stock		 2.61 456 518 558 659 806
Retained Earnings		 -93 -166 -245 -334 -435 -563
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.03 -0.10 -1.29 0.26 0.38

Quarterly Balance Sheets for Oric Pharmaceuticals

This table presents Oric Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 260 238 227 292 274 351 329 302 243
Total Current Assets		 234 199 193 268 232 324 295 279 211
Cash & Equivalents		 49 29 59 104 26 56 50 44 49
Short-Term Investments		 178 165 131 160 201 260 237 228 154
Prepaid Expenses		 6.46 5.03 3.54 4.20 4.94 7.31 8.19 7.06 7.71
Plant, Property, & Equipment, net		 3.01 3.05 3.11 3.25 3.06 2.80 2.88 3.09 3.02
Total Noncurrent Assets		 23 36 30 20 39 24 31 20 28
Long-Term Investments		 11 24 19 9.58 29 15 22 10.00 20
Other Noncurrent Operating Assets		 12 12 11 11 10 9.21 9.30 9.55 8.37
Total Liabilities & Shareholders' Equity		 260 238 227 292 274 351 329 302 243
Total Liabilities		 23 23 24 23 27 22 27 28 23
Total Current Liabilities		 12 13 15 15 19 15 20 21 18
Accounts Payable		 2.09 1.53 1.93 3.19 3.74 2.99 2.31 4.25 5.16
Accrued Expenses		 10 12 13 11 15 12 17 17 12
Total Noncurrent Liabilities		 10 9.89 8.97 8.48 7.98 6.93 6.97 6.83 5.50
Other Noncurrent Operating Liabilities		 10 9.89 8.97 8.48 7.98 6.93 6.97 6.83 5.50
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 237 215 203 269 247 329 302 274 220
Total Preferred & Common Equity		 237 215 203 269 247 329 302 274 220
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 237 215 203 269 247 329 302 274 220
Common Stock		 527 530 561 650 654 789 795 800 812
Retained Earnings		 -289 -313 -358 -381 -407 -460 -492 -526 -593
Accumulated Other Comprehensive Income / (Loss)		 -1.23 -1.75 -0.50 -0.57 -0.37 -0.16 -0.26 0.72 0.21

Annual Metrics And Ratios for Oric Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Oric Pharmaceuticals' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -28.34% -166.92% -5.32% -19.88% -26.21% -29.31%
EBIT Growth		 0.00% -27.74% -161.70% -6.55% -16.37% -20.72% -28.99%
NOPAT Growth		 0.00% -27.71% -159.67% -6.32% -16.35% -20.72% -28.99%
Net Income Growth		 0.00% -25.84% -174.16% -6.80% -13.22% -12.99% -26.96%
EPS Growth		 0.00% -14.85% 76.25% 38.39% -8.70% 12.89% 6.63%
Operating Cash Flow Growth		 0.00% -13.78% -92.36% -31.53% -26.20% -14.03% -31.48%
Free Cash Flow Firm Growth		 0.00% 0.00% -162.00% -4.77% -27.32% -10.21% -35.43%
Invested Capital Growth		 0.00% 0.00% -222.70% -93.23% 20.53% -86.50% -17.23%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -36.27% 6.55% -0.07% -10.27% -5.35%
EBIT Q/Q Growth		 0.00% 0.00% -36.00% 6.51% 0.74% -9.17% -6.04%
NOPAT Q/Q Growth		 0.00% 0.00% -35.69% 6.49% 0.74% -9.17% -6.04%
Net Income Q/Q Growth		 0.00% 0.00% -37.00% 6.52% 2.11% -8.03% -6.65%
EPS Q/Q Growth		 0.00% 0.00% 66.70% -315.63% 2.60% 1.51% -1.67%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -30.87% 2.52% 1.26% -11.65% -3.48%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 8.33% 1.13% -10.75% -3.63%
Invested Capital Q/Q Growth		 0.00% 0.00% -71.10% -49.61% -86.41% -25.17% -53.33%
Profitability Metrics		 - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 96.50% 95.06% 99.59% 99.82% 97.12% 90.90% 89.47%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -30.56% -39.02% -27.98% -35.99% -45.11% -54.73%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 31.29% -20.63% -27.98% -35.99% -45.11% -54.73%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 29.84% -25.43% -28.84% -40.08% -44.94% -52.59%
Net Operating Profit after Tax (NOPAT)		 -16 -20 -52 -55 -64 -78 -100
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -15.44% -11.38% -8.19% -9.79% -9.99% -11.33%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -34.61% -41.14%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -22 -28 -74 -79 -92 -111 -143
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -21 -27 -73 -77 -92 -116 -150
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 3.60 2.12 1.05 2.24 2.34
Price to Tangible Book Value (P/TBV)		 0.00 0.00 3.60 2.12 1.05 2.24 2.34
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.01 -1.01 -1.02 -1.03 -1.04 -1.05
Leverage Ratio		 0.00 1.07 1.04 1.06 1.10 1.12 1.13
Compound Leverage Factor		 0.00 1.02 1.04 1.06 1.07 1.02 1.01
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 202.40% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -102.40% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 10.48 67.48 12.42 3.46 7.83 7.46
Noncontrolling Interest Sharing Ratio		 0.00% 202.40% 47.14% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 16.81 32.96 15.88 13.68 10.39 10.56
Quick Ratio		 0.00 16.65 32.62 15.64 13.40 10.18 10.30
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -19 -49 -52 -66 -72 -98
Operating Cash Flow to CapEx		 -4,071.46% -3,064.19% -9,550.21% -6,340.89% -3,616.12% -10,092.82% -9,483.33%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 -1.19 -3.82 -7.39 -5.87 -11 -13
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -1.19 -2.64 -3.57 1.52 -5.08 -1.89
Enterprise Value (EV)		 0.00 209 750 299 4.88 267 314
Market Capitalization		 120 120 1,044 579 233 502 569
Book Value per Share		 $0.00 ($47.43) $9.40 $6.93 $5.62 $4.11 $3.45
Tangible Book Value per Share		 $0.00 ($47.43) $9.40 $6.93 $5.62 $4.11 $3.45
Total Capital		 0.00 88 290 273 222 224 243
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -89 -294 -280 -228 -235 -256
Capital Expenditures (CapEx)		 0.51 0.77 0.47 0.94 2.08 0.85 1.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -4.51 -5.91 -12 -11 -16 -19
Debt-free Net Working Capital (DFNWC)		 0.00 85 288 225 195 192 237
Net Working Capital (NWC)		 0.00 85 288 225 195 192 237
Net Nonoperating Expense (NNE)		 5.70 6.88 22 24 25 23 28
Net Nonoperating Obligations (NNO)		 0.00 -89 -294 -280 -228 -235 -256
Total Depreciation and Amortization (D&A)		 0.90 1.03 1.27 2.25 -0.08 -5.14 -7.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($3.36) ($2.07) ($2.25) ($1.96) ($1.83)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 36.70M 39.43M 39.66M 51.45M 69.73M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($3.36) ($2.07) ($2.25) ($1.96) ($1.83)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 36.70M 39.43M 39.66M 51.45M 69.73M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($3.36) ($2.07) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 21.94M 37.95M 45.09M 67.38M 71.03M
Normalized Net Operating Profit after Tax (NOPAT)		 -16 -20 -52 -55 -64 -78 -100
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Oric Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Oric Pharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -44.31% -0.29% -14.46% -26.54% -17.43% -48.00% -17.77% -46.33% -31.79% -22.87% -7.57%
EBIT Growth		 -39.22% 3.01% -10.41% -20.76% -11.63% -42.09% -12.90% -44.11% -33.60% -25.91% -12.86%
NOPAT Growth		 -39.22% 3.01% -10.41% -20.76% -11.63% -42.09% -12.90% -44.11% -33.60% -25.91% -12.86%
Net Income Growth		 -34.75% 8.45% -3.39% -13.10% -2.61% -35.89% -4.45% -39.31% -35.67% -28.16% -20.03%
EPS Growth		 -34.04% 10.34% 10.17% 1.96% 30.16% 5.77% 30.19% 10.00% -11.36% -6.12% -13.51%
Operating Cash Flow Growth		 -59.12% 5.86% 9.20% -18.95% -1.68% -58.33% -46.34% -21.19% -46.59% -15.59% -7.78%
Free Cash Flow Firm Growth		 -93.58% -37.12% 1.69% 16.85% 26.78% 0.47% -57.61% -77.55% -87.86% -52.55% 8.00%
Invested Capital Growth		 36.22% 20.53% -96.35% -410.87% -177.75% -86.50% 53.85% -24.26% 4.30% -17.23% -42.34%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -25.80% 12.97% -16.87% 1.10% -16.74% -9.69% 7.01% -22.89% -5.13% -2.27% 18.59%
EBIT Q/Q Growth		 -24.15% 13.91% -16.09% 2.67% -14.76% -9.57% 7.76% -24.24% -6.39% -3.27% 17.32%
NOPAT Q/Q Growth		 -24.15% 13.91% -16.09% 2.67% -14.76% -9.57% 7.76% -24.24% -6.39% -3.27% 17.32%
Net Income Q/Q Growth		 -22.39% 16.04% -14.86% 4.18% -11.04% -11.19% 11.72% -27.80% -8.14% -5.04% 17.31%
EPS Q/Q Growth		 -23.53% 17.46% -1.92% 5.66% 12.00% -11.36% 24.49% -21.62% -8.89% -6.12% 19.23%
Operating Cash Flow Q/Q Growth		 -8.69% 20.66% -34.57% -2.51% 7.09% -23.54% -24.38% 15.11% -12.38% 2.58% -15.97%
Free Cash Flow Firm Q/Q Growth		 -21.57% 14.03% 11.95% 9.64% -7.05% -16.87% -39.43% -1.79% -13.26% 5.10% 15.91%
Invested Capital Q/Q Growth		 -226.09% -86.41% -4.33% 19.44% -77.28% -25.17% 74.19% -116.91% -36.55% -53.33% 68.66%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 96.63% 94.25% 93.25% 91.81% 88.83% 90.14% 86.27% 88.74% 90.21% 91.75% 91.76%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -35.96% -35.99% -39.44% -36.61% -40.33% -45.11% -38.30% -38.79% -45.98% -54.73% -48.45%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -35.96% -35.99% -39.44% -36.61% -40.33% -45.11% -38.30% -38.79% -45.98% -54.73% -48.45%
Return on Equity Simple (ROE_SIMPLE)		 -42.38% 0.00% -44.33% -34.44% -37.68% 0.00% -30.96% -36.63% -43.75% 0.00% -60.46%
Net Operating Profit after Tax (NOPAT)		 -18 -15 -18 -17 -20 -22 -20 -25 -27 -28 -23
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.66% -2.11% -2.57% -2.13% -2.28% -2.73% -1.75% -2.32% -2.88% -3.51% -2.56%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -9.82% - - - -11.39% -10.42%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -26 -22 -26 -25 -29 -31 -29 -36 -38 -40 -33
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -26 -22 -26 -26 -30 -33 -31 -38 -40 -41 -33
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.59 1.05 1.27 1.30 1.33 2.24 2.82 1.58 2.64 2.34 1.80
Price to Tangible Book Value (P/TBV)		 0.59 1.05 1.27 1.30 1.33 2.24 2.82 1.58 2.64 2.34 1.80
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.03 -1.02 -1.01 -1.03 -1.04 -1.02 -1.02 -1.03 -1.05 -1.01
Leverage Ratio		 1.09 1.10 1.10 1.09 1.11 1.12 1.09 1.09 1.11 1.13 1.08
Compound Leverage Factor		 1.05 1.04 1.03 1.00 0.98 1.01 0.94 0.96 1.00 1.03 0.99
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 2.01 4.39 4.83 8.05 5.87 8.87 24.05 9.34 13.62 8.70 7.38
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 14.96 13.68 12.99 18.46 12.26 10.39 21.31 15.08 13.15 10.56 12.00
Quick Ratio		 14.58 13.40 12.76 18.18 12.00 10.18 20.83 14.66 12.82 10.30 11.56
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -20 -17 -15 -14 -14 -17 -24 -24 -27 -26 -22
Operating Cash Flow to CapEx		 -4,817.96% -5,341.12% -6,654.19% -5,220.99% -25,512.99% -42,578.95% -13,846.79% -7,695.20% -6,889.23% -12,810.05% -8,406.46%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.15 -5.87 -6.13 -4.94 -8.75 -11 -2.83 -6.13 -8.37 -13 -4.02
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 1.79 1.52 -3.01 -3.97 -5.60 -5.08 3.30 -1.20 0.38 -1.89 -1.20
Enterprise Value (EV)		 -91 4.88 48 76 74 267 595 168 441 314 173
Market Capitalization		 127 233 257 350 330 502 926 477 723 569 396
Book Value per Share		 $5.43 $5.62 $4.50 $5.96 $4.54 $4.11 $4.88 $4.49 $3.88 $3.45 $3.09
Tangible Book Value per Share		 $5.43 $5.62 $4.50 $5.96 $4.54 $4.11 $4.88 $4.49 $3.88 $3.45 $3.09
Total Capital		 215 222 203 269 247 224 329 302 274 243 220
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -218 -228 -209 -274 -256 -235 -331 -309 -282 -256 -224
Capital Expenditures (CapEx)		 0.40 0.29 0.31 0.41 0.08 0.06 0.22 0.33 0.42 0.22 0.39
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.26 -11 -11 -10 -14 -16 -7.91 -11 -14 -19 -9.91
Debt-free Net Working Capital (DFNWC)		 185 195 178 254 213 192 309 275 258 237 194
Net Working Capital (NWC)		 185 195 178 254 213 192 309 275 258 237 194
Net Nonoperating Expense (NNE)		 6.84 5.36 5.97 5.45 5.40 6.33 4.72 6.75 7.74 8.61 7.12
Net Nonoperating Obligations (NNO)		 -218 -228 -209 -274 -256 -235 -331 -309 -282 -256 -224
Total Depreciation and Amortization (D&A)		 -0.15 -0.37 -0.61 -1.00 -1.67 -1.86 -1.97 -2.02 -1.68 -1.33 -0.58
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.63) ($0.52) ($0.53) ($0.50) ($0.44) ($0.49) ($0.37) ($0.45) ($0.49) ($0.52) ($0.42)
Adjusted Weighted Average Basic Shares Outstanding		 39.58M 39.66M 45.09M 45.65M 57.40M 51.45M 67.35M 70.35M 70.54M 69.73M 71.04M
Adjusted Diluted Earnings per Share		 ($0.63) ($0.52) ($0.53) ($0.50) ($0.44) ($0.49) ($0.37) ($0.45) ($0.49) ($0.52) ($0.42)
Adjusted Weighted Average Diluted Shares Outstanding		 39.58M 39.66M 45.09M 45.65M 57.40M 51.45M 67.35M 70.35M 70.54M 69.73M 71.04M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 39.58M 45.09M 45.09M 54.53M 54.55M 67.38M 67.42M 70.54M 70.57M 71.03M 71.09M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -15 -18 -17 -20 -22 -20 -25 -27 -28 -23
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Key Financial Trends

Oric Pharmaceuticals (NASDAQ:ORIC) reported Q1 2025 results reflecting continued investment in R&D with strong balance sheet liquidity, modest improvements in loss metrics, but ongoing high cash burn as the biopharma progresses its clinical pipeline.

  • Strong liquidity position with $49.3 M in cash & equivalents and $154.4 M in short-term investments, supporting a current ratio of 12.0x and quick ratio of 11.6x.
  • Net cash position of $223.8 M (negative net debt) keeps enterprise value low at $172.6 M versus $396.3 M market cap.
  • R&D expense declined to $24.6 M from $31.97 M in Q4 2024, helping moderate operating cash burn.
  • Q/Q improvement in EPS to –$0.42 from –$0.52 in Q4 ’24, a 19.2% uplift.
  • Q/Q EBITDA and EBIT improved by 18.6% and 17.3%, respectively, vs. Q4 ’24.
  • No reported revenue, consistent with pre-commercial biotech model.
  • Altman Z-Score remains healthy at 7.38, indicating low near-term default risk.
  • No debt on the balance sheet; 100% equity-funded capital structure.
  • Net loss of $30.0 M remains sizable, though narrower than $36.3 M in Q4 ’24.
  • Operating cash flow burn rose to –$32.5 M from –$28.1 M in Q4 ’24, sustaining high quarterly cash outflows.
07/08/25 04:02 AMAI Generated. May Contain Errors.

Frequently Asked Questions About Oric Pharmaceuticals' Financials

When does Oric Pharmaceuticals' financial year end?

According to the most recent income statement we have on file, Oric Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Oric Pharmaceuticals' net income changed over the last 6 years?

Oric Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$127.85 million in 2024, rising from -$21.36 million in 2018. The previous period was -$100.70 million in 2023. See where experts think Oric Pharmaceuticals is headed by visiting Oric Pharmaceuticals' forecast page.

What is Oric Pharmaceuticals' operating income?
Oric Pharmaceuticals' total operating income in 2024 was -$142.90 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $142.90 million
How has Oric Pharmaceuticals' revenue changed over the last 6 years?

Over the last 6 years, Oric Pharmaceuticals' total revenue changed from $0.00 in 2018 to $0.00 in 2024, a change of 0.0%.

How much debt does Oric Pharmaceuticals have?

Oric Pharmaceuticals' total liabilities were at $31.02 million at the end of 2024, a 11.1% increase from 2023, and a 406.9% increase since 2019.

How much cash does Oric Pharmaceuticals have?

In the past 5 years, Oric Pharmaceuticals' cash and equivalents has ranged from $23.38 million in 2023 to $226.01 million in 2021, and is currently $59.41 million as of their latest financial filing in 2024.

How has Oric Pharmaceuticals' book value per share changed over the last 6 years?

Over the last 6 years, Oric Pharmaceuticals' book value per share changed from 0.00 in 2018 to 3.45 in 2024, a change of 344.5%.


Related Companies

This page (NASDAQ:ORIC) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners
F1 Engineering Powers This Electric Marine Motor
The future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...
The Tomorrow Investor | Sponsored
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
Instant Cash (in 4 clicks)
Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...
Awesomely, LLC | Sponsored
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsored
Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...
Paradigm Press | Sponsored